Imaxio signs a license agreement with the German Cancer Research Center (DKFZ)

Imaxio, a biotech company specializing in immunology announces today that it has signed a license agreement with the world-renowned German Cancer Research Center (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed.

It follows a 2-year evaluation of Imaxio’s IMX313P pro-immunogenic technology by DKFZ under a license option agreement. This evaluation has proven the ability of IMX313P to enhance the efficacy of a DKFZ’ vaccine candidate indicated in the prevention of human papillomavirus (HPV) infections, a virus that can lead to cervical cancers. DKFZ has therefore decided to exercise its option right, and to move forward in the development of this IMX313P-based vaccine candidate.

“This deal with a renowned academic institution such as DKFZ is a real acknowledgement of our vaccine technology,” said Alexandre Le Vert, chief executive officer of Imaxio. “It strengthens the confidence we have in our earlyclinical stage pipeline of vaccines based on IMX313P.”

“Being provided with IMX313P increases the probability of our HPV vaccine candidate to reach the market,” added Professor Martin Müller, director of the Research Group Tumorvirus-specific Vaccination Strategies at DKFZ. “We are now ready to move forward with the regulatory development of our IMX313Pbased HPV vaccine candidate.”

According to World Health Organization estimates, cervical cancer affects approximately 450.000 women worldwide each year